Literature DB >> 35867711

Mixed lineage kinase 3 requires a functional CRIB domain for regulation of blood pressure, cardiac hypertrophy, and left ventricular function.

Pei-Wen Liu1,2, Gregory L Martin1, Weiyu Lin1,2, Wanting Huang1,2, Suchita Pande1, Mark J Aronovitz1, Roger J Davis3, Robert M Blanton1,2.   

Abstract

Mixed lineage kinase 3 (MLK3) modulates blood pressure and left ventricular function, but the mechanisms governing these effects remain unclear. In the current study, we therefore investigated the role of the MLK3 Cdc42/Rac interactive binding (CRIB) domain in cardiovascular physiology. We examined baseline and left ventricular pressure overload responses in a MLK3 CRIB mutant (MLK3C/C) mouse, which harbors point mutations in the CRIB domain to disrupt MLK3 activation by Cdc42. Male and female MLK3C/C mice displayed increased invasively measured blood pressure compared with wild-type (MLK3+/+) littermate controls. MLK3C/C mice of both sexes also developed left and right ventricular hypertrophy but normal baseline LV function by echocardiography and invasive hemodynamics. In LV tissue from MLK3C/C mice, map3k11 mRNA, which encodes MLK3, and MLK3 protein were reduced by 74 ± 6% and 73 ± 7%, respectively. After 1-wk LV pressure overload with 25-gauge transaortic constriction (TAC), male MLK3C/C mice developed no differences in LV hypertrophy but displayed reduction in the LV systolic indices ejection fraction and dP/dt normalized to instantaneous pressure. JNK activation was also reduced in LV tissue of MLK3C/C TAC mice. TAC induced MLK3 translocation from cytosolic fraction to membrane fraction in LV tissue from MLK3+/+ but not MLK3C/C mice. These findings identify a role of the MLK3 CRIB domain in MLK3 regulation of basal blood pressure and cardiac morphology, and in promoting the compensatory LV response to pressure overload.NEW & NOTEWORTHY Here, we identified that the presence of two discrete point mutations within the Cdc42/Rac interaction and binding domain of the protein MLK3 recapitulates the effects of whole body MLK3 deletion on blood pressure, cardiac hypertrophy, and left ventricular compensation after pressure overload. These findings implicate the CRIB domain, and thus MLK3 activation by this domain, as critical for maintenance of cardiovascular homeostasis.

Entities:  

Keywords:  cardiac hypertrophy; heart failure; hypertension; mixed lineage kinase; molecular signaling

Mesh:

Substances:

Year:  2022        PMID: 35867711      PMCID: PMC9448288          DOI: 10.1152/ajpheart.00660.2021

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   5.125


  19 in total

1.  Cdc42 induces activation loop phosphorylation and membrane targeting of mixed lineage kinase 3.

Authors:  Yan Du; Barbara C Böck; Karen A Schachter; Mary Chao; Kathleen A Gallo
Journal:  J Biol Chem       Date:  2005-10-27       Impact factor: 5.157

2.  JNK1 is required to preserve cardiac function in the early response to pressure overload.

Authors:  Hideo Tachibana; Cinzia Perrino; Hideyuki Takaoka; Roger J Davis; Sathyamangla V Naga Prasad; Howard A Rockman
Journal:  Biochem Biophys Res Commun       Date:  2006-03-20       Impact factor: 3.575

3.  Cdc42-induced activation of the mixed-lineage kinase SPRK in vivo. Requirement of the Cdc42/Rac interactive binding motif and changes in phosphorylation.

Authors:  B C Böck; P O Vacratsis; E Qamirani; K A Gallo
Journal:  J Biol Chem       Date:  2000-05-12       Impact factor: 5.157

4.  MLK3 regulates bone development downstream of the faciogenital dysplasia protein FGD1 in mice.

Authors:  Weiguo Zou; Matthew B Greenblatt; Jae-Hyuck Shim; Shashi Kant; Bo Zhai; Sutada Lotinun; Nicholas Brady; Dorothy Zhang Hu; Steven P Gygi; Roland Baron; Roger J Davis; Dallas Jones; Laurie H Glimcher
Journal:  J Clin Invest       Date:  2011-10-03       Impact factor: 14.808

5.  Cdc42 is an antihypertrophic molecular switch in the mouse heart.

Authors:  Marjorie Maillet; Jeffrey M Lynch; Bastiano Sanna; Allen J York; Yi Zheng; Jeffery D Molkentin
Journal:  J Clin Invest       Date:  2009-09-08       Impact factor: 14.808

6.  Mixed-lineage kinase 3 pharmacological inhibition attenuates murine nonalcoholic steatohepatitis.

Authors:  Kyoko Tomita; Rohit Kohli; Brittany L MacLaurin; Petra Hirsova; Qianqian Guo; Luz H Gutierrez Sanchez; Harris A Gelbard; Burns C Blaxall; Samar H Ibrahim
Journal:  JCI Insight       Date:  2017-08-03

7.  Pyroptosis and ferroptosis induced by mixed lineage kinase 3 (MLK3) signaling in cardiomyocytes are essential for myocardial fibrosis in response to pressure overload.

Authors:  Junyan Wang; Bo Deng; Qing Liu; Yusheng Huang; Weitao Chen; Jing Li; Zheng Zhou; Lu Zhang; Birong Liang; Jiaqi He; Zixin Chen; Cui Yan; Zhongqi Yang; Shaoxiang Xian; Lingjun Wang
Journal:  Cell Death Dis       Date:  2020-07-24       Impact factor: 8.469

8.  Mixed lineage kinase 3 inhibition induces T cell activation and cytotoxicity.

Authors:  Sandeep Kumar; Sunil Kumar Singh; Navin Viswakarma; Gautam Sondarva; Rakesh Sathish Nair; Periannan Sethupathi; Subhash C Sinha; Rajyasree Emmadi; Kent Hoskins; Oana Danciu; Gregory R J Thatcher; Basabi Rana; Ajay Rana
Journal:  Proc Natl Acad Sci U S A       Date:  2020-03-24       Impact factor: 12.779

9.  The ARRIVE guidelines 2.0: updated guidelines for reporting animal research.

Authors:  Nathalie Percie du Sert; Viki Hurst; Amrita Ahluwalia; Sabina Alam; Marc T Avey; Monya Baker; William J Browne; Alejandra Clark; Innes C Cuthill; Ulrich Dirnagl; Michael Emerson; Paul Garner; Stephen T Holgate; David W Howells; Natasha A Karp; Stanley E Lazic; Katie Lidster; Catriona J MacCallum; Malcolm Macleod; Esther J Pearl; Ole H Petersen; Frances Rawle; Penny Reynolds; Kieron Rooney; Emily S Sena; Shai D Silberberg; Thomas Steckler; Hanno Würbel
Journal:  BMJ Open Sci       Date:  2020-07-20

10.  MLK3 mediates impact of PKG1α on cardiac function and controls blood pressure through separate mechanisms.

Authors:  Timothy D Calamaras; Suchita Pande; Robert Au Baumgartner; Seung Kyum Kim; Joseph C McCarthy; Gregory L Martin; Kelly Tam; Angela L McLaughlin; Guang-Rong Wang; Mark J Aronovitz; Weiyu Lin; Jonathan I Aguirre; Paulina Baca; Peiwen Liu; Daniel A Richards; Roger J Davis; Richard H Karas; Iris Z Jaffe; Robert M Blanton
Journal:  JCI Insight       Date:  2021-09-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.